Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features
Manasa Melachuri(Southern Illinois University School of Medicine), Umamaheswar Duvvuri(City University of New York), Shaum Sridharan(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Terral Patel(University of Pittsburgh Medical Center), Seungwon Kim(UPMC Hillman Cancer Center), Purva Rumde(University of Pittsburgh), Daniel Awad(University of Pittsburgh), Chareeni Kurukulasuriya(Fred Hutch Cancer Center)
Cited by 5
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590